---
company: Spero Therapeutics, Inc.
ticker: SPRO
form: 8-K
filed: 2026-08-12
accession: 0001193125-26-346855
source: https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/
---

# Spero Therapeutics (SPRO) earnings release, August 12, 2026

Spero Therapeutics, Inc. (SPRO) · Form 8-K, Item 2.02 · Filed 2026-08-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/)

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

CAMBRIDGE, Mass., Aug 12, 2026 – Spero Therapeutics, Inc.

(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.

“During the second quarter, we achieved several defining milestones that have fundamentally strengthened Spero’s business. We entered the quarter as a company preparing for an important regulatory milestone and have since then announced the FDA approval of Utebzi; a new Phase

2-ready immunology program with SP001; and financing that positions us to continue executing on our mission to deliver transformative therapies to patients,” said Esther Rajavelu, President and Chief Executive Officer of Spero. “As we look to the remainder of 2026, our priorities are to advance SP001 toward a

Phase 2 study in IgG4-related disease and continue evaluating additional development opportunities in immune-mediated diseases to expand the SP001 value proposition, while maintaining our disciplined approach to execution.”

Recent Business Highlights

Exclusive License

Agreement with Innovent Biologics for SP001

Utebzi (tebipenem pivoxil) U.S. FDA Approval

$105 Million

Non-Recourse,

Non-Dilutive

Royalty Financing

Corporate

Second Quarter 2026 Financial Results

For further details on Spero’s financials, refer to Spero’s Quarterly Report on Form

10-Q, filed with the U.S. Securities and Exchange Commission (SEC) today.

Conference call and webcast

Management will host a conference call and live audio webcast at 5:00 pm EDT today, August 12, to discuss the results and provide a business and pipeline update. To access the call, please dial

1-877-407-0789

(domestic) or

1-201-689-8562

(international) and refer to conference ID 13762082, or click on this link to request a return call. The webcast for the event can be accessed live on this link, or on the Investor Relations page of the Spero Corporate website at https://www.sperotx.com/.

The archived webcast will be available for 30 days following the call.

About SP001

SP001 is a third-generation, potential best-in-class, fully humanized,

Fc-silent

IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in

T-cell,

B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, SP001 has the potential to provide a targeted non-B-cell-depleting treatment across multiple immune-mediated diseases where immune-cell interactions drive chronic inflammation, relapse, and tissue damage. SP001 is designed to address platelet activation concerns associated with earlier anti-CD40L antibodies, while preserving key monoclonal antibody properties, including FcRn interaction that supports

IgG-like half-life.

About Spero Therapeutics

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation,

Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, statements relating to Spero’s plans to advance SP001 into a Phase 2 study in IgG4-related disease; Spero’s plans to explore the use of SP001, and the role of CD40L inhibition, in additional autoimmune and inflammatory diseases; the anticipated benefits of the non-dilutive royalty-backed transaction, including the anticipated use of proceeds; Spero’s expectation that Utebzi will be made available to U.S. patients by the end of 2026; anticipated cash runway, and future milestones. Forward-looking statements are based on Spero’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to the completion and integration of the Innovent transaction; Spero’s ability to successfully develop SP001; the timing and outcome of clinical trials and regulatory interactions; the ability to obtain and maintain regulatory approvals; potential safety, efficacy, manufacturing, supply, intellectual property, financing, competitive, and market risks; and other risks described in Spero’s filings with the Securities and Exchange Commission. Spero undertakes no obligation to update any forward-looking statements, except as required by law.

Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics

IR@Sperotherapeutics.com

Media Inquiries: media@sperotherapeutics.com

Spero Therapeutics, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

Spero Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

## Financial statements

### Income Statement (Three Months Ended June 30, — (unaudited) (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues: | Grant revenue | $— | 2,387 | $— | 3,150 |
| Revenues: | Collaboration revenue - related party |  | 11,802 | 258 | 16,901 |
| Revenues: | Collaboration revenue |  |  |  | 12 |
| Revenues: | Total revenues |  | 14,189 | 258 | 20,063 |
| Operating expenses: | Research and development | 3,434 | 10,672 | 6,343 | 24,278 |
| Operating expenses: | General and administrative | 6,492 | 5,878 | 11,379 | 12,702 |
| Operating expenses: | Restructuring |  | 83 |  | 258 |
| Operating expenses: | Total operating expenses | 9,926 | 16,633 | 17,722 | 37,238 |
| Operating expenses: | Loss from operations | -9,926 | -2,444 | -17,464 | -17,175 |
| Operating expenses: | Total other income, net | 374 | 744 | 709 | 1,609 |
| Operating expenses: | Net loss | -9,552 | -1,700 | -16,755 | -15,566 |
| Operating expenses: | Net loss per share attributable to common shareholders per share, basic and diluted | -0.16 | -0.03 | -0.29 | -0.28 |
| Operating expenses: | Weighted average shares outstanding, basic and diluted: | 57,968,608 | 56,026,767 | 57,626,986 | 55,703,275 |

### Balance Sheet (December 31, — (unaudited) (in thousands))

| | June 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| Cash and cash equivalents | 50,774 | 40,265 |
| Other assets | 1,992 | 28,654 |
| Total assets | 52,766 | 68,919 |
| Total liabilities | 8,562 | 9,898 |
| Total stockholder’s equity | 44,204 | 59,021 |
| Total liabilities and stockholders’ equity | 52,766 | 68,919 |
